Recombinant Hypoxanthine Phosphoribosyltransferase 1 (HPRT1)Homo sapiens (Human)Recombinant protein

HGPRT; HGPRTase; HPRT; Lesch-Nyhan Syndrome; Hypoxanthine-guanine phosphoribosyltransferase

  • Product No.RPA717Hu01
  • Organism SpeciesHomo sapiens (Human)Same name, Different species.
  • SourceProkaryotic expression
  • HostE.coli
  • Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
  • Subcellular LocationCytoplasm
  • Predicted Molecular Mass56.3kDa
  • Accurate Molecular Massn/a(Analysis of differences refer to the manual)
  • Residues & TagsThr3~Ala218 (Accession # P00492) with N-terminal His Tag
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • TraitsFreeze-dried powder
  • Purity> 95%
  • Isoelectric Point6.2
  • ApplicationsSDS-PAGE; WB; ELISA; IP.
  • DownloadInstruction Manual
  • UOM10ug50ug200ug1mg1g
  • FOBUS$ 168US$ 420US$ 840US$ 2520US$ 63000
  • Recombinant Hypoxanthine Phosphoribosyltransferase 1 (HPRT1)Package and Components
  • Recombinant Hypoxanthine Phosphoribosyltransferase 1 (HPRT1)Package and Components
    • RPA717Hu01.jpgSDS-PAGE
    • CertificateISO9001: 2008, ISO13485: 2003 Registered

    SEQUENCE

    USAGE

    Reconstitute in PBS or others.

    STORAGE

    Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

    STABILITY

    The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

    Reference

    • J Crohns Colitis.Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C.Pubmed:25518051
    • J CrohnsResponse to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of tenascin CPubMed: 25518051